BACKGROUND & AIMS: Increased waist circumference and visceral fat are associated with increased risk of Barrett's esophagus (BE) and esophageal adenocarcinoma. This association might be mediated by mechanical and endocrine mechanisms. We investigated the distribution of fat in subjects with BE and its association with esophageal inflammation and dysplasia. METHODS: We collected data from 50 BE cases and 50 controls (matched for age and sex, identified from a radiology trauma database) seen at the Mayo Clinic in 2009. Abdominal (subcutaneous and visceral) and gastroesophageal junction (GEJ) fat area was measured using computed tomography with standard techniques. Esophageal inflammation (based on a histologic score) and dysplasia grade were assessed from esophageal biopsies of BE cases by a gastrointestinal pathologist. Conditional logistic regression was used to assess the association of body fat depot area with BE status, esophageal inflammation, and dysplasia. RESULTS: All BE subjects had controlled reflux symptoms without esophagitis, based on endoscopy. The GEJ fat area (odds ratio [OR], 6.0; 95% confidence interval [CI], 1.3-27.7; P = .02), visceral fat area (OR, 4.9; 95% CI, 1.0-22.8; P = .04), and abdominal circumference (OR, 9.1; 95% CI, 1.4-57.2; P = 0.02) were associated with BE, independent of body mass index (BMI). The subcutaneous fat area was not associated with BE. Visceral and GEJ fat were significantly greater in BE subjects with esophageal inflammation (compared with those without, P = .02) and high-grade dysplasia (compared with those without, P = .01), independent of BMI. CONCLUSIONS: GEJ and visceral fat are associated with BE, and with increased esophageal inflammation and high-grade dysplasia in BE subjects, independent of BMI. Visceral fat therefore might promote esophageal metaplasia and dysplasia.
BACKGROUND & AIMS: Increased waist circumference and visceral fat are associated with increased risk of Barrett's esophagus (BE) and esophageal adenocarcinoma. This association might be mediated by mechanical and endocrine mechanisms. We investigated the distribution of fat in subjects with BE and its association with esophageal inflammation and dysplasia. METHODS: We collected data from 50 BE cases and 50 controls (matched for age and sex, identified from a radiology trauma database) seen at the Mayo Clinic in 2009. Abdominal (subcutaneous and visceral) and gastroesophageal junction (GEJ) fat area was measured using computed tomography with standard techniques. Esophageal inflammation (based on a histologic score) and dysplasia grade were assessed from esophageal biopsies of BE cases by a gastrointestinal pathologist. Conditional logistic regression was used to assess the association of body fat depot area with BE status, esophageal inflammation, and dysplasia. RESULTS: All BE subjects had controlled reflux symptoms without esophagitis, based on endoscopy. The GEJ fat area (odds ratio [OR], 6.0; 95% confidence interval [CI], 1.3-27.7; P = .02), visceral fat area (OR, 4.9; 95% CI, 1.0-22.8; P = .04), and abdominal circumference (OR, 9.1; 95% CI, 1.4-57.2; P = 0.02) were associated with BE, independent of body mass index (BMI). The subcutaneous fat area was not associated with BE. Visceral and GEJ fat were significantly greater in BE subjects with esophageal inflammation (compared with those without, P = .02) and high-grade dysplasia (compared with those without, P = .01), independent of BMI. CONCLUSIONS: GEJ and visceral fat are associated with BE, and with increased esophageal inflammation and high-grade dysplasia in BE subjects, independent of BMI. Visceral fat therefore might promote esophageal metaplasia and dysplasia.
Authors: Michael B Cook; Darren C Greenwood; Laura J Hardie; Christopher P Wild; David Forman Journal: Am J Gastroenterol Date: 2007-11-06 Impact factor: 10.864
Authors: Zoe R Edelstein; Diana C Farrow; Mary P Bronner; Sheldon N Rosen; Thomas L Vaughan Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682
Authors: Joel H Rubenstein; Anne Dahlkemper; John Y Kao; Min Zhang; Hal Morgenstern; Laurence McMahon; John M Inadomi Journal: Am J Gastroenterol Date: 2008-05-28 Impact factor: 10.864
Authors: F Francois; J Roper; A J Goodman; Z Pei; M Ghumman; M Mourad; A Z Olivares de Perez; G I Perez-Perez; C-H Tseng; M J Blaser Journal: Gut Date: 2007-08-30 Impact factor: 23.059
Authors: B J Kendall; G A Macdonald; N K Hayward; J B Prins; I Brown; N Walker; N Pandeya; A C Green; P M Webb; D C Whiteman Journal: Gut Date: 2008-01-04 Impact factor: 23.059
Authors: Douglas A Corley; Ai Kubo; Theodore R Levin; Gladys Block; Laurel Habel; Wei Zhao; Pat Leighton; Charles Quesenberry; Greg J Rumore; Patricia A Buffler Journal: Gastroenterology Date: 2007-04-25 Impact factor: 22.682
Authors: Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2013-05-22 Impact factor: 11.382
Authors: Cadman L Leggett; Eric M Nelsen; Jianmin Tian; Cathy B Schleck; Alan R Zinsmeister; Kelly T Dunagan; G Richard Locke; Kenneth K Wang; Nicholas J Talley; Prasad G Iyer Journal: Mayo Clin Proc Date: 2013-02 Impact factor: 7.616
Authors: Hashem B El-Serag; Ali Hashmi; Jose Garcia; Peter Richardson; Abeer Alsarraj; Stephanie Fitzgerald; Marcelo Vela; Yasser Shaib; Neena S Abraham; Maria Velez; Rhonda Cole; Margot B Rodriguez; Bhupinderjit Anand; David Y Graham; Jennifer R Kramer Journal: Gut Date: 2013-02-13 Impact factor: 23.059
Authors: Cadman L Leggett; Emmanuel C Gorospe; Andrew D Calvin; William S Harmsen; Alan R Zinsmeister; Sean Caples; Virend K Somers; Kelly Dunagan; Lori Lutzke; Kenneth K Wang; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2013-09-11 Impact factor: 11.382